RESULTS	In a subgroup of patients with moderate to severe memory impairment ( n = 81 ) , defined as 25 % impairment or greater on HVLT at baseline , rivastigmine was significantly better than placebo for a number of measures , including the proportion of HVLT responders and CANTAB RVIP mean latency .\